Glial and neuroinflammatory targets for treating substance use disorders

Traditional approaches to treating substance use disorders have focused heavily on modulating neuronal neurotransmitter systems, such as dopamine and glutamate, with limited success. This paper reviews the growing evidence that glial cells—previously considered merely supportive brain cells—play an active role in the development and maintenance of drug addiction. Drugs of abuse, including opioids, psychostimulants, and alcohol, induce neuroinflammatory signals and disrupt glutamate homeostasis by interacting with microglia and astrocytes.

Astrocytes and microglia are key responders to the brain's microenvironment. Astrocytes are critical for regulating glutamate levels through transporters (like GLT-1) and the glutamate-glutamine cycle. When drugs of abuse alter astrocyte function, this leads to impaired glutamate uptake and abnormal extracellular glutamate levels. Simultaneously, drugs of abuse often trigger microglial activation, which acts as an innate immune response, releasing proinflammatory cytokines that can exacerbate neuronal dysfunction and promote drug-seeking behaviors. The paper highlights that stress, another major factor in addiction vulnerability, can prime these cells to become even more reactive to subsequent drug exposure.

Given that glial cells are fundamentally involved in the brain's response to drugs, researchers have begun testing "glial modulators" as a novel category of pharmacotherapy. These include agents like ibudilast (a phosphodiesterase inhibitor), pioglitazone (a PPARγ agonist), and N-acetylcysteine (a cysteine prodrug). Preclinical models have shown significant success in reducing drug self-administration and reinstatement behavior. Clinical trials in humans have also produced promising results, such as reduced withdrawal severity and decreased drug craving, though the translation from animal models to human clinical efficacy remains complex and inconsistent across different studies.